Researchers from the University of Texas Health Science Center have conducted a clinical trial of a drug, Rhenium Obisbemeda, that more than doubled the median survival and progression-free survival times for patients with glioblastoma, a common type of brain tumor. The drug reportedly had no dose-limiting toxic effects and a second phase of trials is due for completion by year’s end.
IXON VPN Vulnerabilities Let Attackers Gain Access to Windows & Linux Systems
A security assessment by Shelltrail revealed three critical vulnerabilities in the IXON VPN client, allowing privilege escalation on Windows and Linux. Identified as CVE-2025-ZZZ-01, CVE-2025-ZZZ-02,
%20CISO%E2%80%99s%20Core%20Focus.webp?w=0&resize=0,0&ssl=1 "Identity and Access Management (IAM)")